Evidence map›Paper›PMID 40301283›Full record

ArticlePharmacoEconomics - open2025

Using Generative Artificial Intelligence in Health Economics and Outcomes Research: A Primer on Techniques and Breakthroughs.

Tim Reason, Sven Klijn, Will Rawlinson, Emma Benbow, Julia Langham, Siguroli Teitsson, Kasper Johannesen, Bill Malcolm

Abstract read
In one paragraph

Article in PharmacoEconomics - open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tim ReasonEstima Scientific, 2 Eastbourne Terrace, London, W2 6LG, UK. tim.reason@estima-sci.com.
Sven KlijnBristol Myers Squibb, Princeton, NJ, USA.
Will RawlinsonEstima Scientific, 2 Eastbourne Terrace, London, W2 6LG, UK.
Emma BenbowEstima Scientific, 2 Eastbourne Terrace, London, W2 6LG, UK.
Julia LanghamEstima Scientific, 2 Eastbourne Terrace, London, W2 6LG, UK.
Siguroli TeitssonBristol Myers Squibb, Uxbridge, UK.
Kasper JohannesenBristol Myers Squibb, Stockholm, Sweden.
Bill MalcolmBristol Myers Squibb, Uxbridge, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of generative artificial intelligence (GenAI) offers the potential to enhance health economics and outcomes research (HEOR) by streamlining traditionally time-consuming and labour-intensive tasks, such as literature reviews, data extraction, and economic modelling. To effectively navigate this evolving landscape, health economists need a foundational understanding of how GenAI can complement their work. This primer aims to introduce health economists to the essentials of using GenAI tools, particularly large language models (LLMs), in HEOR projects. For health economists new to GenAI technologies, chatbot interfaces like ChatGPT offer an accessible way to explore the potential of LLMs. For more complex projects, knowledge of application programming interfaces (APIs), which provide scalability and integration capabilities, and prompt engineering strategies, such as few-shot and chain-of-thought prompting, is necessary to ensure accurate and efficient data analysis, enhance model performance, and tailor outputs to specific HEOR needs. Retrieval-augmented generation (RAG) can further improve LLM performance by incorporating current external information. LLMs have significant potential in many common HEOR tasks, such as summarising medical literature, extracting structured data, drafting report sections, generating statistical code, answering specific questions, and reviewing materials to enhance quality. However, health economists must also be aware of ongoing limitations and challenges, such as the propensity of LLMs to produce inaccurate information ('hallucinate'), security concerns, issues with reproducibility, and the risk of bias. Implementing LLMs in HEOR requires robust security protocols to handle sensitive data in compliance with the European Union's General Data Protection Regulation (GDPR) and the United States' Health Insurance Portability and Accountability Act (HIPAA). Deployment options such as local hosting, secure API use, or cloud-hosted open-source models offer varying levels of control and cost, each with unique trade-offs in security, accessibility, and technical demands. Reproducibility and transparency also pose unique challenges. To ensure the credibility of LLM-generated content, explicit declarations of the model version, prompting techniques, and benchmarks against established standards are recommended. Given the 'black box' nature of LLMs, a clear reporting structure is essential to maintain transparency and validate outputs, enabling stakeholders to assess the reliability and accuracy of LLM-generated HEOR analyses. The ethical implications of using artificial intelligence (AI) in HEOR, including LLMs, are complex and multifaceted, requiring careful assessment of each use case to determine the necessary level of ethical scrutiny and transparency. Health economists must balance the potential benefits of AI adoption against the risks of maintaining current practices, while also considering issues such as accountability, bias, intellectual property, and the broader impact on the healthcare system. As LLMs and AI technologies advance, their potential role in HEOR will become increasingly evident. Key areas of promise include creating dynamic, continuously updated HEOR materials, providing patients with more accessible information, and enhancing analytics for faster access to medicines. To maximise these benefits, health economists must understand and address challenges such as data ownership and bias. The coming years will be critical for establishing best practices for GenAI in HEOR. This primer encourages health economists to adopt GenAI responsibly, balancing innovation with scientific rigor and ethical integrity to improve healthcare insights and decision-making.

Identifiers

PMID40301283
PMCPMC12209483

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.